Ernst et al. show that STAT5A/5B lacking the transactivation domain (ΞTAD) phosphorylate and dimerize normally upon Epo stimulation but accumulate in the cytoplasm instead of the nucleus, while the analogous STAT3-ΞTAD imports even better than wild-type β establishing a STAT5-specific import requirement . The phenotype survives multiple controls: it occurs with N- or C-terminal tags and untagged protein, is unaffected by leptomycin B (not Crm1 export), MG132 (not proteasomal degradation), or K696/K700 acetylation-site mutation .
Deletion mapping narrowed the determinant to a 12-amino-acid stretch (F751βH762), previously implicated in transactivation and turnover . Fusion of just these 12 residues to ΞTAD restored nuclear import, and alanine scanning pinpointed acidic residues D754 and D758 as necessary β but not sufficient, since D754/D758 add-back in a 10A-and2D background failed to rescue . Notably, the hydrophobic residues F751/L753 critical for transactivation are dispensable for import β transactivation and import determinants are separable within one segment.
Using CATCHFIRE chemically induced dimerization, the authors showed a single intact TAD in the pSTAT5 dimer suffices for nuclear import; WT/2Dto2A heterodimers import, while 2Dto2A homodimers are retained and exit the nucleus upon Epo . The authors propose the TAD motif is one half of a composite dimer-specific NLS (dsNLS), analogous in logic to STAT1's dsNLS spanning DBD and SH2 domains.
Strengths: rigorous negative controls, orthogonal confirmation by immunofluorescence of untagged pSTAT5, quantitative N/C ratio time-course imaging, and the elegant CATCHFIRE heterodimer design. Weaknesses: entirely cell-culture based (HeLa/HEK293T), with overexpression and meYFP tags β although tag-position controls mitigate this; no in vivo or primary hematopoietic cell validation; the identity of the putative complementary dsNLS motif and the importin mediating transport remain unknown; exact replicate counts and statistics are not stated in the text . The therapeutic claim (targeting the dsNLS in myeloproliferative neoplasms) is speculative until the full import machinery is molecularly defined. The hypothesis would be falsified if pSTAT5 import were shown to proceed TAD-independently in primary erythroid or leukemic cells, or if a non-TAD compensatory route appeared under physiological expression levels.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.